WHO advises against GLP-1 drugs for children 9 and under as pediatric trials continue
New WHO childhood obesity guidance cites unknown effects on growth and mental health, while Novo, Lilly, AstraZeneca and Pfizer keep testing the drugs in kids.
Recap by typeshit. Full story at Yahoo.